No Data
Hong Kong stocks movement | ALPHAMAB-B (09966) rose over 4% as its differentiated pipeline layout gradually enters a harvest period. Institutions are bullish on its long-term development.
ALPHAMAB-B (09966) rose over 4%, as of the time of writing, it increased by 4.08%, priced at 3.57 Hong Kong dollars, with a transaction volume of 18.34 million Hong Kong dollars.
Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval From CDE to Initiate a Phase III Clinical Study for Ovarian Cancer
Express News | Alphamab Oncology - Approval From Cde China for Jskn003 to Initiate a Phase III- Clinical Study for Treatment of Oc
The clinical study of Corning Jereh's HER2 bispecific antibody ADC subcutaneous injection compound formulation JSKN033 has been approved for clinical trials.
Suzhou, December 26, 2024 /PR Newswire/ -- Corning Jiere Biotechnology (stock code: 9966.HK) announced that the application for a Phase I/II clinical study (Study No: JSKN033-102) of the high-concentration subcutaneous compound formulation JSKN033, a HER2 bispecific antibody-conjugated drug (ADC) combined with a PD-L1 inhibitor, has been approved by the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE). This study is part of the pilot project for optimizing Innovative Drugs clinical trial review and approval. JSKN033-102 is an open, multi-center...
Alphamab Oncology's Anti-Tumor Drug Gets IND Approval From NMPA
ALPHAMAB-B (09966.HK): The IND application for a Phase I/II clinical trial of JSKN033 has been approved by CDE.
On December 24, Gelonghui announced that ALPHAMAB-B (09966.HK) has received approval from the National Medical Products Administration ("NMPA") Drug Evaluation Center ("CDE") for its new drug clinical trial application ("IND") for JSKN033 (a high concentration subcutaneous combined formulation of HER2 bispecific antibody conjugate drug ("ADC") and PD-L1 immune checkpoint inhibitor). JSKN033-102 is an open-label, multi-center, phase I/II clinical trial.
Alphamab Oncology's (HKG:9966) 31% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
No Data
